SETD2-deficient RCC cells display heightened dependence on replication-stress response pathways; preclinical work shows synergy between SETD2 loss and ATR inhibition, with augmented cGAS–STING activation and antitumor immunity. The gene discussed is SETD2; the disease is renal cell carcinoma.